Latest and Past News
-
CHS James Kreppner Memorial Scholarship and Bursary Program
Information including the criteria and application forms for the CHS James Kreppner Memorial Scholarship and Bursary Program is available on the CHS website at www.hemophilia.ca/james-kreppner-memorial-scholarship-and-bursary-program....
-
European Haemophilia Consortium New Products Review
Read the latest research news about innovative coagulation products – factor replacement products, non-factor therapies and gene therapies – in the European Haemophilia Consortium New...
-
Global dosing hold in fitusiran trials initiated by Sanofi Genzyme to investigate new adverse events
A joint statement of the World Federation of Hemophilia (WFH), European Haemophilia Consortium (EHC) and National Hemophilia Foundation (NHF) November 6, 2020 – The WFH,...
-
A Patient Videoconference on Inhibitors & New Novel Therapies – Answering Your Questions!
On November 2, 2020, the CHS held a live educational videoconference aimed to improve the understanding of FVIII/FIX inhibitors and treatment options, with a...
-
Access to Innovative and Curatives Therapies – NRBDO virtual conference
NOVEMBER 5-7 Many innovative and curative therapies are coming to market for rare blood disorders, but will they be available to Canadian patients? What is...
-
COVID-19 updates
Access the most updated information regarding COVID-19 and inherited bleeding disorders: www.hemophilia.ca/covid-19
-
WFH Advisory: availability of desmopressin
WFH Advisory: availability of desmopressin pending re-start of intranasal desmopressin manufacture
-
Products in the pipeline
It is an exciting time in the treatment of people with bleeding disorders with many coagulation products having been recently approved by Health Canada or...
-
Coagulation products
www.hemophilia.ca/coagulation-products
-
WFH publishes 3rd Edition of the Guidelines for the Management of Hemophilia
The World Federation of Hemophilia (WFH) has published the 3rd Edition of the Guidelines for the Management of Hemophilia, replacing the 2nd Edition published in...
-
FDA denies approval of Biomarin’s FVIII gene therapy
In a decision that surprised many, the U.S. Food and Drug Administration (FDA) last week denied approval of Biomarin’s FVIII gene therapy, branded Roctavian. The...
-
Management of comorbidities in bleeding disorders
Three decades of people with hemophilia unexposed to contaminated factor products and current treatments capable of suppressing and eliminating HIV and HCV, respectively, has again...
-
Substitution therapy
Hemlibra (emicizumab) is indicated in Canada for hemophilia A patients with or without factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce the...
-
Plasma Saves Lives: Addressing the COVID-19 Pandemic
The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the...